Future Perspectives of Newborn Screening for Inborn Errors of Immunity

Maartje Blom1, Robbert G M Bredius2, Mirjam van der Burg1

  • 1Laboratory for Pediatric Immunology, Department of Pediatrics, Willem-Alexander Children's Hospital, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.

Insights

Newborn screening (NBS) programs are expanding to include more inborn errors of immunity (IEI) beyond severe combined immunodeficiency (SCID). New technologies show promise for early detection of various IEI, but require careful evaluation before widespread adoption.

Area of Science:

  • Immunology
  • Genetics
  • Public Health

Background:

  • Newborn screening (NBS) programs have expanded, notably with the T-cell receptor excision circle (TREC) assay for severe combined immunodeficiency (SCID).
  • SCID was the first inborn error of immunity (IEI) included in population-based screening, utilizing the first high-throughput DNA-based test in NBS.

Purpose of the Study:

  • To explore the potential of new technologies for early detection of various IEI in newborns.
  • To identify other IEI that could benefit from early diagnosis and intervention through NBS.

Main Methods:

  • Review of technological advancements including KREC analysis, epigenetic immune cell counting, protein profiling, and genomic techniques (NGS, WGS).
  • Assessment of the feasibility of integrating these advanced tests into existing NBS programs.

Main Results:

  • Current NBS primarily screens for SCID using the TREC assay.
  • Emerging technologies like KREC analysis, epigenetic assays, protein profiling, and next-generation sequencing (NGS) offer potential for broader IEI screening.
  • Early detection of various IEI can prevent severe infections, immune dysregulation, and autoimmunity.

Conclusions:

  • Advances in molecular and genomic technologies present opportunities to expand NBS for a wider range of IEI.
  • Further examination of technical, ethical, social, legal, logistical, and cost implications is crucial before incorporating new IEI into NBS programs.

Related Concept Videos

Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
503
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
466
Rh Blood Group01:19

Rh Blood Group

The Rhesus (Rh) antigen is crucial in determining blood groups and ensuring compatibility during blood transfusions.
2.0K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
19
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
27
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
301